Compare ACADIA Pharmaceuticals Inc. (ACAD) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs NextEra Energy, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.52 (market cap $5.07B), while NextEra Energy, Inc. trades at $86.02 (market cap $178.85B). The key difference: NextEra Energy, Inc. is far larger — about 35.3× ACADIA Pharmaceuticals Inc.'s market cap, and NextEra Energy, Inc. pays a 2.91% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | NEE | |
|---|---|---|
Market Cap | $5.07B | $178.85B |
Sector | Health | Utilities |
52-Week High | $29.41 | $97.88 |
52-Week Low | $20.06 | $69.77 |
Enterprise Value | $4.19B | $286.18B |
Dividend Yield | — | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
NextEra Energy (NEE) trades at $84.70, showing minimal daily movement. The stock exhibits a bearish technical signal despite recent earnings beats in Q1 and Q2 2026. Financially, the company maintains strong profitability with a 32.4% net income margin and benefits from growing electricity demand driven by AI data center expansion, as highlighted in recent partnerships like the $100 billion Kentucky data center project with Brookfield (The Motley Fool, 2026-07-29).
Outlook remains positive due to robust dividend payments and strategic positioning in AI power infrastructure, though risks include high capital expenditures and rising debt levels. Analyst consensus is bullish with a $100.40 price target, suggesting significant upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
